News articles about Thoratec (NASDAQ:THOR) have trended somewhat negative recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Thoratec earned a coverage optimism score of -0.19 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 47.4173246855828 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

ILLEGAL ACTIVITY NOTICE: “Thoratec (THOR) Receives Daily Media Impact Rating of -0.19” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/06/thoratec-thor-receives-daily-media-impact-rating-of-0-19.html.

Thoratec Company Profile

Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company’s products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD).

Insider Buying and Selling by Quarter for Thoratec (NASDAQ:THOR)

Receive News & Stock Ratings for Thoratec Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thoratec Co. and related stocks with our FREE daily email newsletter.